[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"skin-texture\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:skin-texture":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,40],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":15,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":28,"lastUpdatePostDateStruct":29,"startDateStruct":32,"completionDateStruct":34,"leadSponsor":36,"locationsCount":39},"100613049","characterization-of-skin-and-facial-fat-pad-thickness-changes-following-microneedling-radiofrequency-with-and-without-topical-poly-l-lactic-acid-for-facial-rejuvenation-100613049",false,"NCT07261527","Characterization of Skin and Facial Fat Pad Thickness Changes Following Microneedling Radiofrequency With and Without Topical Poly-L-Lactic Acid for Facial Rejuvenation","Inclusion Criteria:\n\n* Seeking facial rejuvenation for cosmetic concerns\n* Able and willing to provide informed consent\n* Willing to comply with study procedures and follow-up visits\n\nExclusion Criteria:\n\n* Prior filler injection or energy-based device treatment to the face within the past 6 months\n* Previous facial surgeries\n* Pregnant or breastfeeding\n* Active infection, dermatitis, or open lesions in the treatment area\n* History of keloids or abnormal scarring\n* Known allergy to poly-L-lactic acid (PLLA)- Current participation in another clinical trial involving facial aesthetic treatments\n* Presence of pre-cancerous or cancerous lesions in the treatment area\n* Current or planned use of glucagon-like peptide-1 receptor agonists (e.g., Ozempic, semaglutide) during the study period. Subjects on these medications will be excluded due to potential effects on facial fat and overall weight.\n* HIV+ patients\n* Patients on HIV medications- Patients that have eczema and rosacea",true,"ALL","18 Years",{"count":19,"type":20},30,"ESTIMATED","INTERVENTIONAL",[23],"NA","The purpose of this study is to evaluate whether microneedling RF subcutaneous fat pad thickness in the temple, submental, and cheek regions, to determine whether the addition of topical PLLA after microneedling RF alters or preserves subcutaneous fat pad thickness and to assess patient satisfaction and perceived outcomes following microneedling RF ± PLLA treatment.",[26],"Skin Texture","NOT_YET_RECRUITING","2025-11-22",{"date":30,"type":31},"2025-12-03","ACTUAL",{"date":33,"type":20},"2025-11-24",{"date":35,"type":20},"2027-11-30",{"name":37,"class":38},"The University of Texas Health Science Center, Houston","OTHER",1,{"id":41,"slug":42,"hasResults":11,"nctId":43,"briefTitle":44,"officialTitle":44,"acronym":4,"eligibilityCriteria":45,"healthyVolunteers":11,"sex":16,"minAge":46,"maxAge":47,"enrollmentInfo":48,"targetDuration":4,"studyType":21,"phases":50,"briefSummary":53,"conditions":54,"keywords":62,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":66,"lastUpdatePostDateStruct":67,"startDateStruct":69,"completionDateStruct":71,"leadSponsor":73,"locationsCount":5},"100582895","phase-1-autologous-adipose-cells-therapy-100582895","NCT06869252","Autologous Adipose Cells Therapy","Inclusion Criteria:\n\n1. Outpatients who express interest in skin rejuvenation, and\u002For who are experiencing skin conditions, such as winkles, fine lines, loss of skin elasticity, skin pigmentation, scarring.\n2. Outpatients who are experiencing hair loss or hair thinning\n3. Provision of signed and dated informed consent form\n4. Clearly stated willingness to comply with all the procedures of the study and availability of the study\n5. Female and Male aged between 21 to 80 years old 6 Medical clearance by family doctor\n\nExclusion Criteria:\n\n1. Pregnancy or lactation\n2. Known allergic reaction to components of cell culture media\n3. Chronic disease , e.g. cardiovascular disease, diabetes, chronic kidney disease, seizures\n4. Chronic infections, e.g. skin fungi infection, psoriasis\n5. Chronic wound healing\n6. Currently taking hormone therapy\n7. History of cancers and active cancers\n8. Viral infection, e.g. HIV, hepatitis B, influenza, coronaviruses.","21 Years","80 Years",{"count":49,"type":20},40,[51,52],"PHASE1","PHASE2","Autologous Adipose Cell Therapy is a series of process designated to address the demerits of the traditional autologous fat grafting and dermal fillers, while enhancing the versatility and aesthetic outcomes. In this study, the goal is to evaluate the safety and efficacy of Autologous Adipose cell Therapy for skin rejuvenation and hair improvement in human application.",[55,56,57,58,59,60,61,26],"Hair Loss\u002FBaldness","Wrinkle Appearance","Volume","Fine Lines","Skin Elasticity","Hair Thinning","Skin Pigmentation",[63,64],"Adipose Cells","Adipocytes","RECRUITING","2025-05-30",{"date":68,"type":31},"2025-05-31",{"date":70,"type":20},"2025-08-01",{"date":72,"type":20},"2026-02-01",{"name":74,"class":75},"CERM INC.","INDUSTRY"]